Mydecine Innovations reports positive pre-clinical data for MYCO-003 and updates on patent progress

Mydecine Innovations Group Inc (OTCMKTS:MYCOF) (NEO:MYCO) Chief Science Office Robert Roscow tells Proactive it has reported positive pre-clinical data for its drug MYCO-003 as a treatment for anxiety and post-traumatic stress disorder (PTSD) and updated on the candidate’s patent progress. Colorado-headquartered Mydecine also said it had now filed its final patent application for the drug… Read More »